Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
Monte Rosa's broad molecular glue degrader plan comes unstuck
Biomarker-positive patients were rarer than expected in some tumor types, prompting the biotech to focus MRT-2359 development on prostate cancer.
Nick Paul Taylor
Mar 20, 2025 10:07am
Novartis hands over $55M to license preclinical hives prospect
Mar 3, 2025 5:05pm
Novartis inks $925M Anthos takeover to rejoin clot-busting race
Feb 11, 2025 5:21am
Pfizer taps ex-Novartis leader to helm cancer R&D work
Feb 6, 2025 10:45am
Novartis gives up on anti-CD40 antibody to treat Sjögren's
Jan 31, 2025 5:13am
Will Novartis catch the PD-1 bispecific wave? CEO weighs in
Jan 31, 2025 3:30am
